About

It is a today common opinion that the vast potential of Real-World Data (RWD) is a valuable resource not only for disease understanding but also for product development, health technology assessment and market access.
In this context is very much important to understand the pivotal role of research methods in collecting Real World Evidence (RWE) to support regulatory decisions and /or to allow a strategic use of clinical RWD.

This 2-step intensive course will allow you to learn how to setup a methodologically sound RWD collection able to generate RWE, focusing on several critical success factors: methodological, regulatory and operational.

Gain insights into navigating the digital health era, understanding regulations that impact real-world research, and effectively organising and conducting data collections.

Step 1 of this course empowers you with essential knowledge, covering topics like methodological and technical aspects of real-world studies, different study designs and applications and how to manage the complexity of a very heterogenous regulatory environment.

Step 2 explores the concept of "study-project dualism" in real-world research, where study and project objectives may not align entirely. Grasp the strategic design phase's importance in overcoming organizational and cultural barriers, involving various stakeholders from clinical R&D, marketing, market access, and more.

A remote homework, between step 1 and 2, will allow you to consolidate the notions and concepts learned by applying them to a real case taken from your company context, which you can then use to deepen the advanced design techniques that will be exposed in the second part of the course, learning from a well-established methodology, honed through the successful design of numerous observational studies, how to align study and project objectives seamlessly.

PROGRAM STEP 1: METHODS, VALUE AND REGULATIONS

 MODULE 1 | DEFINITION AND METHODS

  • Methodological characteristics of RWD collections
  • Types of data collections (aims versus study designs)
  • Primary data and secondary use of existing data; the “hybrid studies”

MODULE 2 | THE VALUE OF RWE

  • The value of RWD: an historical overview. Current and future impact of RWD on life sciences product development
  • Limits of the observational methods in generating RWE

MODULE 3 | REGULATIONS AND GUIDELINES

  • International regulatory framework
  • Ethical and administrative authorization processes
  • Special cases: off-label drugs and EAP; additional diagnostic procedures; registries; hybrid studies;

 

PROGRAMM STEP 2: STRATEGIES FOR RWE GENERATION

 MODULE 4 | THE PROJECT DESIGN

  • Methodological introduction to “project” (the strategy) and “study” (the tool) design
  • The strategic use of RWD in the pre- and post-marketing phases
  • Case studies and exercises

 MODULE 5 | DEVELOPMENT OF A CONCEPT SHEET

  • From the strategy to the study: how to combine business with ethical and scientific objectives in clinical research
  • The executive design phases: from study scenarios to the concept sheet
  • Case studies and exercises

Step 1 is highly recommended for curious people who want to systematically explore the fascinating and complex methodologies of RWD use in the context of clinical research, and especially for professionals already working or starting to work in Medical Affairs, Market Access, Regulatory,  Drug Development/Clinical Research, Real World Evidence Generation functions of Life Sciences companies.

Step 1+2 (whole course) is recommended for those in decision-making and coordinating roles in Medical Affairs, Clinical Research, Real World Evidence Generation who must generate pre- and post-marketing Real World Evidences to support corporate product development and define strategies to market access.

 

Participant’s experience
Familiarity with clinical research is useful.

Highly interactive training and discussion of real cases.

Lecturers
Giovanni Fiori
Info

Giovanni Fiori

RWE Advise & Projects

He holds a PhD in the Biology of Human Populations and a master’s in public health. Since 1994 he has conducted epidemiological research as part of international cooperation programs in Central Asia led by the University of Bologna. In 2003 he was the founder, president (until August 2018) and scientific director (until March 2022) of Medineos (formerly MediData Studi e Ricerche) where, in addition to developing the business, he was responsible for defining the strategy for designing and conducting more than 150 local and international Real World multi-centre observational studies for the pharmaceutical industry and non-profit organisations. Together with French, German, Czech and Spanish colleagues, he was one of the founders of the European observational research network WellCRO. From 2018 to 2022, following the entry of Medineos into the IQVIA group, he also held the position of Senior Principal Observational Study in the Italian branch. Since 2005 he has been the coordinator of the “Observational Studies and Real-World Evidence” Working Group of the Italian Society of Pharmaceutical Medicine (SiMeF, ex SSFA), where he was also a board member of directors. At the European level, he was responsible for the “Late Phase” working group of the European CRO Federation (EUCROF). He regularly teaches the Master of Clinical Research at the Bicocca University of Milan. Invited as a speaker at various congresses & conferences, he is the author or co-author of over a hundred articles and scientific communications.


Online Training – 5 modules

STEP 1
Module 1 | 08 May 2024 from 9:30 am to 12:30 pm CEST
Module 2 | 15 May 2024 from 9:30 am to 12:30 pm CEST
Module 3 | 22 May 2024 from 9:30 am to 12:30 pm CEST

STEP 2
Module 4 | 10 October 2024 from 9:30 am to 12:30 pm CEST
Module 5 | 17 October 2024 from 9:30 am to 12:30 pm CEST

After the registration, you will receive all details about the connection.

The course will proceed with a minimum number of participants. Should this number not be reached the registered participants will be notified one week prior to the commencement of the course.

STEP 1 

Early Bird: € 945,00* (until 17 April 2024)

Ordinary: € 1.155,00*

Freelance – Individual – Academy – Public Administration**: € 615,00*

 

STEP 1+2 (whole course)

Early Bird: € 1.450,00* (until 17 April 2024)

Ordinary: € 1.790,00*

Freelance – Individual – Academy – Public Administration**: € 930,00*

 

* for Italian companies: +22% VAT

** Early Bird discount not applicable to Freelance – Individual – Academy – Public Administration fee

The fee includes: tuition, organizational office assistance, teaching materials and attendance certificate that will be sent after the training via e-mail.

Printable Version
At the end of the training, you will be able to
Risultato atteso
Correctly define what RWD is from both a methodological and regulatory prospectives
Risultato atteso
Understand the usefulness and limitations of RWD to generate RWE, and how to capture its value both pre- and post-marketing
Risultato atteso
Set up a RWD collection, taking into account the regulatory aspects and organizational constraints associated with observational clinical research.
Risultato atteso
Recognize the strategic value and scope of RWD
Risultato atteso
Conduct the design phase of a RWD collection, combining strategic project objectives with the scientific nature of the study

<p><span>Online interactive training on Zoom platform. </span></p>
<p><em>LS Academy will provide the access link to the virtual platform a few days before the training.</em></p>

Online interactive training on Zoom platform. 

LS Academy will provide the access link to the virtual platform a few days before the training.

<p><span>Online interactive training on Zoom platform. </span></p>
<p><em>LS Academy will provide the access link to the virtual platform a few days before the training.</em></p>